NCT05377229: MarginProbe 2.0 Data Collection Protocol

NCT05377229
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be planning to undergo lumpectomy or partial mastectomy procedure
Exclusions: 
https://ClinicalTrials.gov/show/NCT05377229

Comments are closed.

Up ↑